Skip to main content

Chronic Use of NSAIDs May Decrease Skin Cancer Risk


May 29, 2012 — Use of nonsteroidal anti-inflammatory drugs (NSAIDs) may decrease the risk for developing squamous cell carcinoma (SCC) or malignant melanoma (MM), according to a new population-based, case-control study published online May 29 in Cancer.
Use of NSAIDs overall (>2 prescriptions) was associated with a decreased risk for SCC (incidence rate ratio [IRR], 0.85; 95% confidence interval [CI], 0.76 - 0.94) and MM (IRR, 0.87; 95% CI, 0.80 - 0.95) compared with nonuse (≤2 prescriptions). This was especially true for long-term use (≥7 years) and high-intensity use (>25% prescription coverage during the total duration of use). Although NSAID use was not associated with a reduced risk for basal cell carcinoma (BCC) overall (IRR, 0.97; 95% CI, 0.93 - 1.01), a reduced risk for BCC at sites other than the head was noted with long-term use (IRR, 0.85; 95% CI, 0.76 - 0.95) and high-intensity use (IRR, 0.79; 95% CI, 0.69 - 0.91).
"The effect [of NSAIDs] increased with greater duration and intensity of use, which may reflect a cumulative biologic effect (ie, a dose-response effect) exerted in the initiation of carcinogenesis," write Sigrun Alba Johannesdottir, BSc, from the Department of Clinical Epidemiology, Aarhus University Hospital, Denmark, and colleagues.
The researchers note that the NSAIDs associated with reduced risk were primarily nonselective NSAIDs and older cyclooxygenase (COX)-2 inhibitors (diclofenac, etodolac, and meloxicam). Unlike other studies, "[o]ur results do not support an association between newer COX-2 inhibitors and skin cancer or NSAIDs overall and BCC. However, our findings are in accordance with studies conducted in the general population. Thus, the effects of NSAIDs may depend on the baseline risk of skin cancer," the authors write.
Using the Danish Cancer Registry (DCR), the authors identified all cases of SCC, MM, and BCC diagnosed in individuals 20 years of age or older in northern Denmark from 1991 through 2009. The researchers identified 1974 diagnoses of SCC, 13,316 diagnoses of BCC, and 3242 diagnoses MM.
Information on the site of the cancer was collected, and patients with a history of disorders known to increase the risk for skin cancer (HIV, a previous cancer diagnosis, or history of solid organ transplantation) were excluded.
The investigators used the Danish Civil Registry System to match 10 population control individuals to each case patient based on age, sex, and country of residence. They also used the system to collect information regarding NSAID use. Patients with a history of rheumatoid arthritis, migraines, or cardiovascular disease were identified and these diseases used as proxy measures for chronic NSAID use.
The median age of patients at the time of diagnosis was 77 years, 67 years, and 57 years for SCC, BCC, and MM, respectively. Patients diagnosed with SCC were predominately men (63%), with tumors frequently located on the head and neck (56%). Men accounted for 50% of patients diagnosed with BCC and 45% of patients diagnosed with MM.
The authors acknowledge that analysis of newer COX-2 inhibitors was curtailed by the fact that they were only available during part of the study period and, in some instances, were withdrawn from the market. Results may also have been biased because only 60% of SCC and BCC cases are recorded in the DCR. In addition, the study relied on dispensed prescriptions, which may not accurately reflect actual drug use both among prescription and over-the-counter NSAID users. The authors note, however, that repeated refills for the same medications likely implies adherence to a prescribed treatment regime.
"Given the high skin cancer incidence and the widespread and frequent use of NSAIDs, a preventive effect of these agents may have important public health implications," the authors note.
"We observed that NSAIDs overall, including aspirin, other nonselective NSAIDs, and older COX-2 inhibitors, were associated with a decreased risk of skin cancer, particularly SCC and MM," they conclude.
Funding for this study was provided by the Clinical Epidemiological Research Foundation. The authors have disclosed no relevant financial relationships.

Comments

Post a Comment

Popular posts from this blog

Contact Precautions May Have Unintended Consequences

Contact precautions, including gloves, gowns, and isolated rooms, have helped stem the transmission of hospital pathogens but have also had some negative consequences, according to findings from a new study. Healthcare worker (HCWs) visited patients on contact precautions less frequently than other patients and spent less time with those patients when they did visit, report Daniel J. Morgan, MD, from the University of Maryland School of Medicine and the Veterans Affairs (VA) Maryland Health Care System, Baltimore, and colleagues. Moreover, patients on contact precautions also received fewer outside visitors. "Less contact with HCWs suggests that other unintended consequences of contact precautions still exist," Dr. Morgan and coauthors write. "The resulting decrease in HCW contact may lead to increased adverse events and a lower quality of patient care due to less consistent patient monitoring and poorer adherence to standard adverse event prevention methods (such...
Post a Comment
Read more

CareFusion Issues Update on Infant Breathing Product Recall

July 5, 2012 — Medical device maker CareFusion has issued an update reminding healthcare providers of its voluntary recall of its Air Life ™ Infant Breathing Circuit, initiated back in May. The US Food and Drug Administration (FDA) has classified this action as a class 1 recall, meaning there is a reasonable probability of serious adverse health consequences or death associated with use of the defective units. The update was posted July 2 on the FDA  Website. On May 29, 2012, CareFusion sent an  Urgent Recall Notice  to customers and distributors stating that the company had identified potential risks associated with the Air Life  Infant Breathing Circuit. The action was initiated after the company received complaints of the Y adapter within the breathing circuit developing cracks during patient use. "If a crack develops in the Y adapter, this could potentially result in a leak in the closed ventilation system, leading to a loss in the intended tidal volum...
Post a Comment
Read more

FDA Approves Tapentadol ER for Diabetic Neuropathy

August 29, 2012 — The US Food and Drug Administration (FDA) has approved tapentadol extended-release (ER) ( Nucynta , Janssen Pharmaceuticals, Inc) for the management of neuropathic pain associated with diabetic peripheral neuropathy (DPN) in adults for whom a continuous opioid analgesic is required over an extended time. It is the first opioid to receive this indication, the company notes in a statement today. DPN, the most common type of neuropathy, affects an estimated 16% of the more than 25 million Americans who have diabetes. The condition is often unreported and untreated, with an estimated 2 out of 5 cases not receiving care. Tapentadol ER is already approved for the treatment of moderate to severe chronic pain in adults requiring a continuous opioid analgesic for an extended period. It is a centrally acting synthetic analgesic, although the exact mechanism of action is unknown, the release states. "Although the clinical relevance is unclear," the company n...
4 comments
Read more